Alzamend Neuro (NASDAQ:ALZN) Posts Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Alzamend Neuro (NASDAQ:ALZN) posted its quarterly earnings data on Thursday. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.12), FiscalAI reports.

Alzamend Neuro Price Performance

ALZN stock opened at $1.72 on Friday. The business’s 50-day moving average is $1.44 and its two-hundred day moving average is $1.37. The firm has a market capitalization of $8.30 million, a P/E ratio of -0.75 and a beta of 0.23. Alzamend Neuro has a 1 year low of $0.84 and a 1 year high of $2.68.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 31st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Alzamend Neuro presently has a consensus rating of “Hold” and an average price target of $28.00.

Institutional Trading of Alzamend Neuro

A hedge fund recently raised its position in Alzamend Neuro stock. DRW Securities LLC boosted its position in Alzamend Neuro, Inc. (NASDAQ:ALZN) by 27.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 116,319 shares of the company’s stock after acquiring an additional 25,074 shares during the quarter. DRW Securities LLC owned 3.06% of Alzamend Neuro worth $212,000 at the end of the most recent quarter. 49.61% of the stock is currently owned by institutional investors.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.